IQVIA Holdings (IQV) Peer Comparison
$270.97
$0.60
(0.22%)
As on 28-Sep-2026 16:00EDT
Market cap
$44,113 Mln
Revenue (TTM)
$16,983 Mln
P/E Ratio
33.4
P/B Ratio
7.2
Div. Yield
0 %
Edit
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
44,113 | 133,369 | 81,133 | 79,400 | 43,933 |
Revenue ($ Mln) |
16,983 | 12,624 | 15,535 | 2,228 | -- |
Net Profit ($ Mln) |
1,375.00 | 4,405.20 | 4,328.70 | -3,151.00 | -1,768.29 |
Net Margin (%) |
8.10 | 34.89 | 27.86 | -141.43 | -- |
RoE (%) |
21.63 | 22.64 | 13.75 | -40.89 | -83.46 |
Price to Earnings |
33.37 | 30.24 | 19.49 | -- | -- |
Price-To-Book |
7.17 | 6.46 | 2.60 | 10.75 | 15.69 |
Income Statement ($ Mln)
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
16,983.00 | 12,624.30 | 15,534.70 | 2,228.00 | 0.00 |
|
Cost of Revenue
|
12,528.00 | 1,762.80 | 2,352.10 | 2,508.00 | 9.24 |
|
Gross Profit
|
4,286.00 | 10,267.50 | 12,242.20 | 1,076.00 | -16.56 |
|
Operating Expenses
|
2,150.00 | 5,989.90 | 9,212.50 | 3,040.00 | 1,618.01 |
|
Operating Profit (EBIT)
|
2,305.00 | 4,872.00 | 3,970.10 | -3,320.00 | -1,627.25 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,609.00 | 5,274.90 | 5,166.00 | -3,087.00 | -1,768.29 |
|
Provision for Tax
|
253.00 | 869.30 | 837.30 | 64.00 | 0.00 |
|
Profit after Tax (Net Income)
|
1,375.00 | 4,405.20 | 4,328.70 | -3,151.00 | -1,768.29 |
|
Minority Interest
|
-4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
845.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
6,171.00 | 20,247.90 | 31,711.00 | 6,761.00 | 2,606.24 |
|
Minority Interest
|
-4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
14,765.00 | 3,237.50 | 4,488.60 | 1,666.00 | 1,362.97 |
|
Current Liabilities
|
8,815.00 | 3,937.90 | 5,530.60 | 2,534.00 | 354.06 |
|
Total Liabilities
|
29,944.00 | 26,142.80 | 40,558.70 | 12,338.00 | 2,354.51 |
Assets ($ Mln)
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
23,655.00 | 14,879.60 | 23,284.00 | 5,146.00 | 294.93 |
|
Current Assets
|
6,226.00 | 12,543.70 | 18,446.00 | 5,815.00 | 4,028.34 |
|
Total Assets
|
29,944.00 | 26,142.80 | 40,558.70 | 12,338.00 | 2,354.51 |
|
Total Debt*
|
16,241.00 | 1,977.60 | 1,986.60 | 1,287.00 | 641.93 |
|
Net Current Assets
|
-2,589.00 | 8,605.80 | 12,915.40 | 3,281.00 | 3,674.28 |
Cashflow ($ Mln)
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2,654.00 | 3,631.40 | 4,978.90 | -1,873.00 | -897.74 |
|
Cash Flow from Investing Activities
|
-2,305.00 | -945.40 | -629.10 | 1,946.00 | 118.06 |
|
Cash from Financing Activities
|
-150.00 | -2,261.30 | -3,715.40 | 593.00 | 621.52 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.34 | 19.42 | 13.65 | -25.41 | -53.99 |
|
ROE (%)
|
21.63 | 22.64 | 13.75 | -40.89 | -83.46 |
|
ROA (%)
|
3.67 | 14.80 | 9.71 | -23.27 | -48.50 |
|
EBIT Margin (%)
|
13.81 | 41.83 | 33.61 | -137.79 | -- |
|
Net Margin (%)
|
8.10 | 34.89 | 27.86 | -141.43 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
8.17 | 10.56 | 9.29 | -27.19 | -- |
|
EBIT Growth (%)
|
5.30 | 20.31 | 6.31 | -4.74 | -33.90 |
|
Net Profit Growth (%)
|
11.16 | 21.10 | -2.91 | -8.54 | -117.75 |
|
EPS Growth (%)
|
16.60 | 22.80 | 1.72 | -6.34 | -95.21 |
|
Book Value Growth (%)
|
9.72 | 19.36 | 7.70 | -29.52 | 24.65 |
Valuation Ratios
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
28.49 | 29.37 | 18.42 | -4.10 | -13.39 |
|
Price / Book Value
|
5.96 | 6.22 | 2.65 | 1.34 | 9.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
15.24 | 23.31 | 13.25 | -3.01 | -12.17 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
2.22 | 0.00 | 0.06 | 0.09 | 0.19 |
|
Short term debt to equity ratio
|
0.37 | 0.00 | 0.00 | 0.01 | 0.01 |
|
Current Ratio
|
0.71 | 3.19 | 3.34 | 2.29 | 11.38 |
|
Quick Ratio
|
0.71 | 2.74 | 2.78 | 2.18 | 11.38 |
|
Interest Coverage
|
3.09 | 800.23 | 94.25 | -72.50 | -28.80 |
Operating Efficiency Ratios
| IQVIA Holdings (IQV) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.94 | 16.91 | 42.26 | 4.62 | -- |
|
Asset Turnover
|
0.45 | 0.42 | 0.35 | 0.16 | 0.00 |
|
Receivable days
|
74.65 | 55.39 | 152.19 | 82.29 | -- |
|
Inventory Days
|
-- | 292.28 | 546.66 | 56.81 | -- |
|
Payable days
|
68.15 | 88.40 | 150.27 | 151.91 | 1,312.97 |
|
Cash Conversion Cycle
|
-- | 259.28 | 548.59 | -12.81 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
